Fulcrum Therapeutics Inc. (FULC) Prices 4M Share Common Offering at $11/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/8/2026
- S&P 500, Nasdaq rise as tech, chipmakers rebound
- Oil prices settle $1 higher after Iran and Israel say they have halted attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Powerful Philippine quake leaves at least 32 feared dead, survivors recount fear
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- SpaceX sets $135 price for blockbuster IPO, upending Wall Street convention
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
January 19, 2021 10:34 PM ESTCAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share, for total gross proceeds of $44.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum. All of the shares in the offering are being sold by Fulcrum. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to... More
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
January 19, 2021 10:34 PM ESTCAMBRIDGE,Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share, for total gross proceeds of $44.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum. All of the shares in the offering are being sold by Fulcrum. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up... More
